naltrexone has been researched along with Chemical Dependence in 251 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 72 (28.69) | 18.7374 |
| 1990's | 56 (22.31) | 18.2507 |
| 2000's | 57 (22.71) | 29.6817 |
| 2010's | 58 (23.11) | 24.3611 |
| 2020's | 8 (3.19) | 2.80 |
| Authors | Studies |
|---|---|
| Adapa, ID; Auh, JS; Berzetei-Gurske, IP; Brandt, SR; Craymer, K; Farrington, L; Haggart, D; Kennedy, JM; O'Brien, A; Polgar, WE; Rodriguez, L; Schwartz, RW; Toll, L; White, A | 1 |
| Carroll, FI | 1 |
| Worley, J | 2 |
| Donohoe, T; Garner, BR; Gordon, T; Gotham, HJ; Knudsen, HK; Loyd, K; Martin, EG; Toro, AK; Tueller, SJ; Zulkiewicz, BA | 1 |
| Boss, R; Buchanan, AL; Coderre, T; Goedel, WC; Krieger, MS; Lebeau, R; Marshall, BDL; Paull, K; Rich, JD; Thompson, C; Yedinak, JL | 1 |
| Etuk, R; Kraus, SW; Potenza, MN | 1 |
| Hulme, J; Sheikh, H; Wiercigroch, D | 1 |
| Kenny, PJ; O'Brien, CP; Pierce, RC; Swinford-Jackson, SE; Unterwald, EM; Vanderschuren, LJMJ | 1 |
| Azar, MR; Cunningham, JI; Dean, RL; Deaver, DR; Eyerman, DJ; Koob, GF; Todtenkopf, MS | 1 |
| Arranz, B; Arrojo, M; Becoña, E; Bernardo, M; Castells, X; Cunill, R; Flórez, G; Fonseca, F; Garriga, M; Goikolea, JM; González-Pinto, A; López, A; Sáiz, PA; San, L; Tirado-Muñoz, J; Torrens, M; Zorrilla, I | 1 |
| English, K; Gu, LY; Madden, EF; Mensah, NA; Qeadan, F; Venner, KL | 1 |
| Brumback, B; Bryant, K; Cohen, M; Cook, RL; Hu, X; Karki, M; Mai, D; Rathore, M; Thoma, K; Weber, KM; Young, M | 1 |
| Bernstein, SL; D'Onofrio, G | 1 |
| Astrup, A; Christensen, R; Johansen, KGV; Lund, H; Pagsberg, AK; Tarp, S | 1 |
| Cousins, SJ; Crèvecoeur-MacPhail, D; Denering, L; Kim, T; Rawson, RA | 1 |
| Gupta, T; Jain, S; Nebhinani, N; Singhai, K; Suthar, N | 1 |
| Negus, SS; Sakloth, F | 1 |
| Hughes, JR; Klemperer, EM; Naud, S | 1 |
| Bullmore, ET; Deakin, B; Elliott, R; Ersche, KD; Flechais, R; Lingford Hughes, A; McGonigle, J; Murphy, A; Nestor, LJ; Nutt, DJ; Orban, C; Paterson, LM; Rabiner, I; Reed, L; Robbins, TW; Sahakian, BJ; Smith, D; Suckling, J; Taylor, E | 1 |
| Grahan, B | 1 |
| Blokhina, E; Burakov, A; Bushara, N; Gross, R; Krupitsky, E; Langleben, D; Lioznov, D; Mamontova, O; Masalov, D; Palatkin, V; Poole, S; Verbitskaya, E; Vetrova, M; Woody, G; Yaroslavtseva, T; Zvartau, E | 1 |
| Rosenberg, L | 1 |
| Castaño-Duque, CH; Dávalos, A; Dorado-Bouix, L; García-Esperón, C; Gomis-Cortina, M; Hervás-García, JV; Jiménez-González, M; López-Cancio Martinez, E; Millán-Torné, M; Pérez de la Ossa-Herrero, N | 1 |
| Douaihy, AB; Kelly, TM; Sullivan, C | 1 |
| Schellekens, A | 1 |
| Iheanacho, T; Issa, M; Marienfeld, C; Rosenheck, RA | 1 |
| Cummings, GR; Heinrich, CJ | 1 |
| Altarifi, AA; Negus, SS; Rice, KC | 1 |
| Spada, MM | 1 |
| Duffy, S; Glanville, JM; Godfrey, C; Hewitt, C; Martyn-St James, M; McCool, R; Neilson, M; Perry, AE | 1 |
| Benneyworth, MA; Kalyuzhny, AE; Le Naour, M; Lunzer, MM; Portoghese, PS; Powers, MD; Thomas, MJ | 1 |
| Friedmann, PD; Park, TW | 1 |
| Ko, MC; Lagorio, CH; Sukhtankar, DD | 1 |
| Ghanbari, A; Mahmoodi, M; Moradi, M; Raoofi, A | 1 |
| Bachtell, R; Hutchinson, MR; Maier, SF; Rice, KC; Wang, X; Watkins, LR | 1 |
| Glanville, JM; Godfrey, C; Hewitt, C; Martyn-St James, M; Neilson, M; Perry, AE; Woodhouse, R | 1 |
| Willyard, C | 1 |
| Abbott, S; Boyapati, V; Deakin, JF; Elliott, R; Erritzoe, D; Ersche, KD; Faluyi, Y; Faravelli, L; Fernandez-Egea, E; Flechais, RS; Kalk, NJ; Kuchibatla, SS; Lingford-Hughes, AR; McGonigle, J; Metastasio, A; Mick, I; Murphy, A; Nestor, L; Nutt, DJ; Orban, C; Passetti, F; Paterson, LM; Rabiner, EA; Reed, LJ; Robbins, TW; Smith, DG; Suckling, J; Tait, R; Taylor, EM; Waldman, AD | 1 |
| Batki, SL; Coffin, P; DeMartini, A; Euren, J; Hahn, JA; Huffaker, S; Matheson, T; Rowe, C; Santos, D; Santos, GM; Vittinghoff, E; Vlahov, D | 1 |
| Alpert, E; Asnaani, A; Foa, EB; Kaczkurkin, AN | 1 |
| Cabrera, EA; Lindgren, E; Miller, G; Volkow, ND; Wang, GJ; Wiers, CE | 1 |
| Creedon, TB; Hodgkin, D; Horgan, CM; Matteucci, AM; Reif, S; Stewart, MT | 1 |
| Klein, JW | 1 |
| Courtney, KE; Ghahremani, DG; Ray, LA | 1 |
| Aboujaoude, E; Salame, WO | 1 |
| Bardo, MT; Beckmann, JS; Hofford, RS | 1 |
| Griffin, N; Guo, S; Hu, X; Shan, F; Wang, X; Yi, Z; Zhang, X | 1 |
| Bullmore, ET; Deakin, B; Elliott, R; Ersche, KD; Flechais, R; Lingford-Hughes, A; McGonigle, J; Murphy, A; Nestor, LJ; Nutt, DJ; Orban, C; Paterson, LM; Rabiner, I; Reed, L; Robbins, TW; Sahakian, B; Smith, D; Suckling, J; Tait, R; Taylor, E | 1 |
| Baek, K; Bullmore, ET; Deakin, B; Elliott, R; Ersche, KD; Flechais, R; Lingford-Hughes, AR; McGonigle, J; Morris, LS; Murphy, A; Nestor, LJ; Nutt, DJ; Orban, C; Passetti, F; Paterson, LM; Rabiner, I; Reed, L; Robbins, TW; Sahakian, BJ; Smith, D; Suckling, J; Tait, R; Taylor, EM; Voon, V | 1 |
| Correia, M; Deakin, JF; Elliott, R; Ersche, KD; Flechais, RS; Lingford-Hughes, AR; McGonigle, J; Murphy, A; Nutt, DJ; Orban, C; Passamonti, L; Paterson, LM; Reed, LJ; Riccelli, R; Robbins, TW; Sahakian, BJ; Savulich, G; Smith, DG; Suckling, J; Tait, R; Taylor, EM | 1 |
| Cousins, SJ; Crèvecoeur-MacPhail, D; Kim, T; Rawson, RA | 1 |
| Newman, RG | 1 |
| Capps, B; Carter, A; Hall, W | 1 |
| DeFulio, A; Iati, C; Needham, M; Silverman, K | 1 |
| Metzger, DS; Zhang, Y | 1 |
| Goldman, D; Heinz, A; Ho, MK; Kaprio, J; Kreek, MJ; Li, MD; Munafò, MR; Tyndale, RF | 1 |
| Capone, C; Kahler, CW; O'Malley, SS; Swift, RM | 1 |
| Abe, N; Gracious, B; Sundberg, J | 1 |
| Alam, DA; Martorana, A | 1 |
| Abraham, AJ; Knudsen, HK; Roman, PM | 1 |
| Abraham, AJ; Kovas, AE; McNulty, T; Rieckmann, T; Roman, PM | 1 |
| Dodrill, CL; Helmer, DA; Kosten, TR | 1 |
| Ciric, S; Johnson, FK; Setnik, B; Stauffer, J; Webster, LR | 1 |
| Flynn, PM; Friedmann, PD; Frisman, LK; Gordon, M; Hall, E; Hoskinson, R; Kinlock, T; Knight, K; Knudsen, HK; O'Connell, DJ; Sacks, S; Schwartz, R; Shafer, MS; Stein, LA; Welsh, WN | 1 |
| Penetar, DM | 1 |
| Clark, DB | 1 |
| Blokhina, E; Föhr, J; Kiviniemi, V; Krupitsky, E; Kuoppasalmi, K; Mamontova, O; Tiihonen, J; Tuomola, P; Verbitskaya, E; Zwartau, E | 1 |
| Reece, AS | 1 |
| Aklin, WM; Bigelow, GE; Defulio, A; Donlin, WD; Dunn, KE; Everly, JJ; Fingerhood, M; Leoutsakos, JM; Nuzzo, PA; Silverman, K; Umbricht, A | 1 |
| Dundon, WD; O'Brien, CP; Pettinati, HM | 1 |
| Butelman, E; Kreek, MJ; LaForge, KS | 1 |
| Modesto-Lowe, V; Van Kirk, J | 1 |
| Gray, RW; Yeomans, MR | 1 |
| Holtzman, SG | 2 |
| Fan, LW; Ho, IK; Ma, T; Park, Y; Rockhold, RW; Sasaki, K; Tanaka, S; Tien, LT | 1 |
| O'Brien, CP | 3 |
| Colker, AC | 1 |
| Brewer, C; Streel, E | 1 |
| Kranzler, HR; Mark, TL; Song, X | 1 |
| Bailey, KP | 1 |
| Kosten, TR; Sofuoglu, M | 1 |
| Hagan, JJ; Heidbreder, CA | 1 |
| Solhkhah, R; Wilens, TE | 1 |
| Baker, B; Baldini-Rossi, N; Hollander, E; Pallanti, S; Sood, E | 1 |
| Cropsey, KL; St Clair, CL; Villalobos, GC | 1 |
| Oslin, DW | 1 |
| Miller, MC | 1 |
| Nestler, EJ; Tamminga, CA | 1 |
| Beilby, JJ; Doran, CM; Duszynski, KM; Mattick, RP | 1 |
| Beard, L; Brown, ES; Dobbs, L; Rush, AJ | 1 |
| Jasmin, L; Narasaiah, M; Tien, D | 1 |
| Chawarski, MC; Mazlan, M; Schottenfeld, RS | 1 |
| Green, AI | 1 |
| Ducharme, LJ; Knudsen, HK; Roman, PM | 1 |
| Brunette, MF; Drake, RE; Green, AI; Noordsy, DL | 1 |
| Kuehn, BM | 1 |
| Holtzman, SG; Michaels, CC | 1 |
| Brunette, MF; Green, AI; Noordsy, DL; O'Keefe, C | 1 |
| Hulse, GK; Tait, RJ | 1 |
| Batey, RG | 1 |
| Brewer, CL | 1 |
| Choy, W; Khong, E | 1 |
| Kunøe, N; Waal, H | 1 |
| D'Amelio, R; Falkai, P; Wobrock, T | 1 |
| Petry, N; Stitzer, M | 1 |
| Gardner, TJ; Kosten, TR | 1 |
| Greenwald, MK | 1 |
| Oser, CB; Roman, PM | 2 |
| Saitz, R | 1 |
| Berglund, M; Gorelick, D; Hesselbrock, V; Johnson, BA; Kranzler, HR; Möller, HJ; Soyka, M | 1 |
| Stitzer, ML; Vandrey, R | 1 |
| Tyndale, R | 1 |
| Cerdeño Impuesto, V | 1 |
| Bakharev, VD; Tikhomirov, SM | 1 |
| Martin, WR | 2 |
| Ayhan, IH; Portoghese, PS; Takemori, AE; Tulunay, FC | 1 |
| Carr, KD | 1 |
| Dackis, CA; Gold, MS | 1 |
| Arndt, I; McLellan, AT; O'Brien, CP | 1 |
| Gmerek, D; Woods, JH | 1 |
| Charney, DS; Galloway, MP; Heninger, GR; Kleber, HD; Murberg, M; Redmond, DE; Roth, RH | 1 |
| Mazze, RI; Saunders, L; Spiegelman, WG | 1 |
| Rawson, RA; Resnick, RB; Tennant, FS; Washton, AM | 1 |
| Eades, CG; Gilbert, PE; Martin, WR; Thompson, JA | 1 |
| Anton, RF; Hogan, I; Jalali, B; Kleber, HD; Riordan, CE | 1 |
| Crain, SM; Shen, KF | 2 |
| Wodak, A | 1 |
| Braida, D; Colombo, M; Gori, E; Groppetti, A; Parenti, M; Sacco, S; Sala, M | 1 |
| Gianoulakis, C | 1 |
| Hoffer, PB; Krystal, JH; McMahon, TJ; O'Connor, PG; Rosen, MI; Sullivan, M; Thomas, HM; van Dyck, CH; Wallace, EA; Woods, SW | 1 |
| Miguel, N; Patricio, LD | 1 |
| Brent, PJ; Cantarell, PA; Chahl, LA; Kavanagh, C | 1 |
| Bailey, MD; Bhargava, HN; Bozek, PS; Gerk, PM; Ko, KH; Matwyshyn, GA; Simko, RJ; Thorat, SN | 1 |
| Bowen, WD; Miyamoto, Y; Portoghese, PS; Takemori, AE | 1 |
| Bar-Hamburger, R; Gandacu, D; Ginath, Y; Porat, S; Shufman, EN; Witztum, E | 1 |
| Ho, IK; Hoskins, B; Jaw, SP; Makimura, M; Oh, KW | 2 |
| Gallino, G; Liffredo, C | 1 |
| Ehrenreich, H; Poser, W | 1 |
| Kaneto, H; Takahashi, M; Tokuyama, S | 1 |
| Ho, IK; Hoskins, B; Jaw, SP; Makimura, M | 1 |
| KOSTEN, TR | 1 |
| Miyamoto, Y; Portoghese, PS; Takemori, AE | 1 |
| Ho, IK; Hoskins, B; Jaw, SP | 1 |
| Greenwood, J; Seivewright, NA | 1 |
| Schuckit, MA | 1 |
| Berg, BJ; Pettinati, HM; Volpicelli, JR | 1 |
| Hajak, G; Poser, W; Rodenbeck, A; Rüther, E; Staedt, J; Stoppe, G; Wassmuth, F | 1 |
| Measom, MO | 1 |
| Bigelow, GE; Garner, JE; Preston, KL; Sullivan, JT; Walsh, SL | 1 |
| Cramer, CM; Hubbell, CL; Pabello, NG; Reid, LD | 1 |
| Isaacs, G; Lerner, AG; Oyefe, I; Sigal, M | 1 |
| Compton, P; Pasero, CL | 1 |
| Ho, IK; Hoshi, K; Ma, T; Oh, S | 1 |
| Glick, SD; Maisonneuve, IM; Pearl, SM | 1 |
| McLellan, AT; O'Brien, CP | 1 |
| Gingras, J; Hepburn, MJ; Kuhn, CM; Little, PJ | 1 |
| Lin, CE; Mello, NK; Negus, SS; Portoghese, PS | 1 |
| Huber, A; Ling, W; McCann, MJ; Miotto, K; Rawson, RA; Shoptaw, S | 1 |
| Rumball, D; Williams, J | 1 |
| Miller, NS; Smith, DE | 1 |
| Hoehn-Saric, R; Legl, T; Lehofer, M; Liebmann, PM; Moser, M; Pernhaupt, G; Schauenstein, K | 1 |
| Fawcett, JP; Morgan, NC; Woods, DJ | 1 |
| McMillen, BA | 1 |
| Biderman, D; Dermatis, H; Galanter, M; Keller, DS | 1 |
| Cramer, CM; Hubbell, CL; Reid, LD | 1 |
| Barke, RA; Loh, HH; Roy, S | 1 |
| Savchenkov, VA; Sivolap, IuP | 1 |
| Allen, JP; Litten, RZ | 1 |
| Bigot-Viale, A; Granry, JC; Pierrot, M; Tesson, B; Vigue, JP | 1 |
| Koyuncuoglu, H; Nurten, A; Nurten, R; Yamantürk, P | 1 |
| Easterling, KW; Holtzman, SG; Plovnick, RM | 1 |
| Alvarez-Fuentes, J; Caraballo, I; Fernández-Arévalo, M; Holgado, MA; Micó, JA; Rojas-Corrales, MO | 1 |
| Farrell, M; Keaney, F | 1 |
| Del Mundo, A; Kauffmann, C; Pumariega, AJ; Vance, HB | 1 |
| Flannery, BA; Monterosso, JR; O'Brien, CP; Oslin, DW; Pettinati, HM; Rukstalis, M; Volpicelli, JR | 1 |
| Yarborough, WH | 1 |
| Basch, J; Ling, W; McCann, M; Miotto, K; Rawson, R | 1 |
| Bowen, CA; Fischer, BD; Mello, NK; Negus, SS | 1 |
| Johnson, JA; Roman, PM | 1 |
| Ladewig, D | 1 |
| Greenstein, R; O'Brien, C | 1 |
| Ary, M; Chesarek, W; Lomax, P; Sorensen, SM | 1 |
| Archer, S; Michne, WF | 1 |
| Greenstein, R; O'Brien, CP; Woody, GE | 1 |
| Kestenbaum, RS; Resnick, RB; Thomas, MA; Washton, AM | 1 |
| Willette, RE | 1 |
| Resnick, RB; Washton, AM | 1 |
| Greenstein, R; O'Brien, CP; Ternes, J; Woody, GE | 1 |
| Gilbert, PE; Martin, WR | 1 |
| Greenstein, R; Hanna, N; Mintz, J; O'Brien, C; Woody, G | 1 |
| Bradford, A; Dorrier, C; Golondzowski, O; Hurley, F | 1 |
| Hollister, LE | 1 |
| Gerwirtz, D; Hurzeler, M; Kleber, H | 1 |
| Curran, S; Savage, C | 1 |
| Keegan, J; Lavenduski, C; Schooff, K | 1 |
| Cooperstein, J; Harris, M; Hough, G; Kauders, F; Resnick, R; Thomas, M | 1 |
| Brahen, L; Capone, T; Wiechert, V | 1 |
| Black, R; Hersch, R; Lewis, D; Mayer, J | 1 |
| Frank, S; Malspeis, L; Notari, RE; Reuning, RH | 2 |
| Kestenbaum, RS; Poole, D; Resnick, RB; Washton, A | 1 |
| Hollister, LE; Kasper, P; Schwin, RL | 1 |
| Swanson, DA | 1 |
| Ary, M; Lomax, P | 1 |
| Freedman, AM; Kestenbaum, RS; Resnick, RB; Volavka, J | 1 |
| Wikler, A | 1 |
| Amico, L; Landsberg, R; Plumb, M; Taintor, Z; Wicks, N | 1 |
| Chen, RC; Ho, AK | 1 |
| Jaffe, J | 1 |
| Goldstein, A | 1 |
| Kauders, F; Schecter, A | 1 |
| Howes, JF; Schwope, AD; Wise, DL | 2 |
| Thies, C | 1 |
| Bocalu, A; Gelkopf, M; Lerner, AG; Sigal, M | 1 |
| Abdelhamid, EE; Portoghese, PS; Sultana, M; Takemori, AE | 1 |
| Ferrari, A; Ferretti, C; Pini, LA; Sternieri, E; Trenti, T | 1 |
| Kosten, TA; Kosten, TR | 1 |
| Fudala, PJ; Heishman, SJ; Henningfield, JE; Johnson, RE | 1 |
| Fukagawa, Y; Misawa, M; Nagase, H; Suzuki, T | 1 |
| Eames, B | 1 |
| Woody, G | 1 |
| Schuster, CR; Snyder, M | 1 |
| Gava, R; Murri, R; Schifano, F | 1 |
| Bedate, J; Cami, J; Forteza-Rei, J; García-Alonso, F; Gutierrez, M; López-Alvarez, M; Palop, R; Pérez de los Cobos, JC; Rodríguez-Artalejo, F; San, L | 1 |
| Valentino, RJ; Wehby, RG | 1 |
| Gold, MS; Jonas, JM | 1 |
| Childress, AR; McLellan, AT | 1 |
| Van Ree, JM | 1 |
| Jacobson, AE | 1 |
| Kleber, HD; Kosten, TR; Morgan, C | 1 |
| Mello, NK; Mendelson, JH | 1 |
| Kleber, HD; Kosten, TR; Kreek, MJ; Ragunath, J | 1 |
| McLellan, AT; Nyberg, F; O'Brien, CP; Terenius, LY | 1 |
| Dixon, R; Simpkins, JW; Smulkowski, M; Tuttle, R | 1 |
| Brahen, LS; Capone, DM; Capone, TJ | 1 |
| Kleber, HD; Kosten, TR; Vining, E | 1 |
| Williams, A | 1 |
| Cook, CC; Lipsedge, MS | 1 |
| Charney, DS; Heninger, GR; Kleber, HD | 1 |
| Dzoljic, MR; Ukponmwan, OE; vd Poel-Heisterkamp, AL | 1 |
| Gmerek, DE; Woods, JH | 1 |
66 review(s) available for naltrexone and Chemical Dependence
| Article | Year |
|---|---|
2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy.
Topics: Animals; Biogenic Monoamines; Biological Transport; Carrier Proteins; Cocaine; Fluorescent Dyes; Humans; Isoquinolines; Ligands; Morphinans; Narcotic Antagonists; Piperidines; Protein Binding; Radioisotopes; Receptors, Opioid; Structure-Activity Relationship; Substance-Related Disorders | 2003 |
Current pharmacotherapy for gambling disorder: a systematic review.
Topics: Behavior, Addictive; Diagnosis, Dual (Psychiatry); Gambling; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy; Randomized Controlled Trials as Topic; Substance-Related Disorders | 2020 |
Clinical practice guideline on pharmacological and psychological management of adult patients with an anxiety disorder and comorbid substance use.
Topics: Adult; Anxiety Disorders; Desipramine; Humans; Naltrexone; Paroxetine; Substance-Related Disorders | 2022 |
Harms associated with taking nalmefene for substance use and impulse control disorders: A systematic review and meta-analysis of randomised controlled trials.
Topics: Disruptive, Impulse Control, and Conduct Disorders; Humans; Naltrexone; Substance Withdrawal Syndrome; Substance-Related Disorders | 2017 |
Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for alcohol use disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Randomized Controlled Trials as Topic; Substance-Related Disorders; Taurine; Treatment Outcome | 2018 |
Medication Treatment For Substance Abuse.
Topics: Adult; Buprenorphine; Female; Humans; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Patient Compliance; Patient Safety; Quality of Life; Risk Assessment; Severity of Illness Index; Substance-Related Disorders; Treatment Outcome; United States | 2019 |
[Ingestion of anabolic steroids and ischaemic stroke. A clinical case report and review of the literature].
Topics: Adult; Alcoholism; Anabolic Agents; Brain Ischemia; Cerebral Angiography; Clenbuterol; Doping in Sports; Fibrinolytic Agents; Humans; Infarction, Middle Cerebral Artery; Male; Martial Arts; Mechanical Thrombolysis; Naltrexone; Nandrolone; Nandrolone Decanoate; Stanozolol; Steroids; Substance-Related Disorders; Testosterone Propionate; Tissue Plasminogen Activator; Tomography, X-Ray Computed | 2013 |
Medications for substance use disorders.
Topics: Alcohol Deterrents; Alcoholism; Analgesics, Opioid; Behavior Therapy; Behavior, Addictive; Buprenorphine; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Secondary Prevention; Smoking Cessation; Substance Withdrawal Syndrome; Substance-Related Disorders; Tobacco Use Disorder | 2013 |
[Pharmacogenetics and the treatment of addiction].
Topics: Genetic Variation; Humans; Naltrexone; Pharmacogenetics; Precision Medicine; Substance-Related Disorders; Treatment Outcome | 2013 |
An overview of problematic internet use.
Topics: Antidepressive Agents, Second-Generation; Behavior, Addictive; Central Nervous System Stimulants; Citalopram; Cognitive Behavioral Therapy; Comorbidity; Disruptive, Impulse Control, and Conduct Disorders; Humans; Internet; Methylphenidate; Mood Disorders; Naltrexone; Narcotic Antagonists; Prevalence; Substance-Related Disorders | 2014 |
Pharmacological interventions for drug-using offenders.
Topics: Adult; Buprenorphine; Criminals; Female; Heroin; Humans; Male; Methadone; Naltrexone; Narcotics; Randomized Controlled Trials as Topic; Substance-Related Disorders | 2013 |
Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders.
Topics: Acamprosate; Analgesics, Opioid; Behavior, Addictive; Buprenorphine; Directive Counseling; Disulfiram; Humans; Methadone; Naltrexone; Narcotic Antagonists; Practice Patterns, Physicians'; Substance-Related Disorders; Taurine; United States | 2014 |
Targeting the Toll of Drug Abuse: The Translational Potential of Toll-Like Receptor 4.
Topics: Animals; Central Nervous System; Humans; Naltrexone; Narcotic Antagonists; Neuroglia; Neurons; Reward; Substance-Related Disorders; Toll-Like Receptor 4; Xenobiotics | 2015 |
Pharmacological interventions for drug-using offenders.
Topics: Adult; Buprenorphine; Crime; Criminals; Female; Heroin; Humans; Male; Methadone; Naltrexone; Narcotics; Opiate Substitution Treatment; Randomized Controlled Trials as Topic; Substance-Related Disorders | 2015 |
Neuroimaging the Effectiveness of Substance Use Disorder Treatments.
Topics: Clinical Trials as Topic; Cognitive Behavioral Therapy; Craving; Humans; Methadone; Naltrexone; Neurofeedback; Neuroimaging; Substance-Related Disorders; Treatment Outcome | 2016 |
Pharmacotherapy for Substance Use Disorders.
Topics: Age Factors; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Buprenorphine; Bupropion; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Substance Withdrawal Syndrome; Substance-Related Disorders; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2016 |
Naltrexone: A Pan-Addiction Treatment?
Topics: Animals; Behavior, Addictive; Evidence-Based Medicine; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy; Randomized Controlled Trials as Topic; Substance-Related Disorders | 2016 |
Drug treatment as HIV prevention: expanding treatment options.
Topics: Alcoholism; Buprenorphine; Clinical Protocols; Drug Users; Health Promotion; HIV Infections; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Risk Reduction Behavior; Risk-Taking; Substance Abuse, Intravenous; Substance-Related Disorders | 2010 |
Breaking barriers in the genomics and pharmacogenetics of drug addiction.
Topics: Genetic Testing; Genetic Variation; Genomics; Humans; Methadone; Naltrexone; Pharmacogenetics; Substance-Related Disorders | 2010 |
Addiction treatment: level of care determination.
Topics: Acamprosate; Alcohol Deterrents; Behavior Therapy; Cognitive Behavioral Therapy; Health Status Indicators; Humans; Inpatients; Mass Screening; Naltrexone; Narcotic Antagonists; Outpatients; Primary Health Care; Substance-Related Disorders; Taurine | 2011 |
Prescription pain medication dependence.
Topics: Analgesics; Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Pain; Prescription Drugs; Substance-Related Disorders | 2011 |
Clinical safety of 1500 mg oral naltrexone overdose.
Topics: Administration, Oral; Adult; Alcoholism; Behavior, Addictive; Dose-Response Relationship, Drug; Drug Overdose; Female; Follow-Up Studies; Humans; Maximum Tolerated Dose; Naltrexone; Narcotic Antagonists; Patient Safety; Risk Assessment; Substance-Related Disorders | 2010 |
Current status of co-occurring mood and substance use disorders: a new therapeutic target.
Topics: Alcoholism; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Diagnosis, Dual (Psychiatry); Double-Blind Method; Drug Therapy, Combination; Humans; Mood Disorders; Naltrexone; Narcotic Antagonists; Psychotropic Drugs; Sertraline; Substance-Related Disorders | 2013 |
Pharmacotherapy of addictions.
Topics: Alcoholism; Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu; Substance-Related Disorders | 2002 |
Clinical uses of naltrexone: a review of the evidence.
Topics: Alcoholism; Animals; Behavior, Addictive; Cocaine-Related Disorders; Feeding and Eating Disorders; Humans; Naltrexone; Narcotic Antagonists; Obsessive-Compulsive Disorder; Opioid-Related Disorders; Schizophrenia; Self-Injurious Behavior; Substance-Related Disorders; Tobacco Use Disorder | 2002 |
Opioid peptides and the control of human ingestive behaviour.
Topics: Alcoholism; Appetite Regulation; Drinking Behavior; Feeding Behavior; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Obesity; Opioid Peptides; Receptors, Opioid; Reward; Substance-Related Disorders; Time Factors; Water Intoxication | 2002 |
Research advances in the understanding and treatment of addiction.
Topics: Acamprosate; Alcohol Deterrents; Brain; Chronic Disease; Disease Progression; Humans; Naltrexone; Narcotics; Prognosis; Recurrence; Risk Factors; Substance-Related Disorders; Taurine | 2003 |
Behavioral health issue brief: pharmacotherapy treatment of alcoholism and drug addiction: overview and bibliography: year end report-2002.
Topics: Alcohol Deterrents; Alcoholism; Analgesics, Opioid; Buprenorphine; Drug Therapy; Humans; Methadone; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Substance-Related Disorders; United States | 2002 |
Learning the language of abstinence in addiction treatment: some similarities between relapse-prevention with disulfiram, naltrexone, and other pharmacological antagonists and intensive "immersion" methods of foreign language teaching.
Topics: Adaptation, Psychological; Alcohol Deterrents; Alcoholism; Behavior Control; Disulfiram; Humans; Language; Naltrexone; Narcotic Antagonists; Secondary Prevention; Substance-Related Disorders; Teaching | 2003 |
Pharmacological treatments for substance use disorders.
Topics: Adrenergic beta-Antagonists; Alcohol Deterrents; Anti-Anxiety Agents; Benzodiazepines; Buprenorphine; Disulfiram; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Neurobiology; Neuropharmacology; Psychopharmacology; Substance Withdrawal Syndrome; Substance-Related Disorders | 2004 |
Pharmacologic management of relapse prevention in addictive disorders.
Topics: Administration, Cutaneous; Administration, Oral; Alcohol Deterrents; Alcoholism; Behavior, Addictive; Disulfiram; Humans; Naltrexone; Narcotics; Nicotine; Smoking Cessation; Smoking Prevention; Substance-Related Disorders | 2004 |
Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving.
Topics: Alcoholism; Clinical Trials as Topic; Cocaine-Related Disorders; Humans; Naltrexone; Narcotic Antagonists; Nicotine; Opioid-Related Disorders; Structure-Activity Relationship; Substance-Related Disorders; Tobacco Use Disorder | 2005 |
Pharmacotherapy of adolescent alcohol and other drug use disorders.
Topics: Adolescent; Adolescent Behavior; Alcohol-Induced Disorders; Disulfiram; Humans; Naltrexone; Substance-Related Disorders | 1998 |
Pharmacological treatments of pathological gambling.
Topics: Antidepressive Agents, Second-Generation; Behavior, Addictive; Bupropion; Comorbidity; Disruptive, Impulse Control, and Conduct Disorders; Dose-Response Relationship, Drug; Fluvoxamine; Gambling; Humans; Naltrexone; Outcome Assessment, Health Care; Paroxetine; Piperazines; Research Design; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders; Triazoles | 2005 |
Anticraving medications for relapse prevention: a possible new class of psychoactive medications.
Topics: Alcoholism; Behavior, Addictive; Bupropion; Cocaine-Related Disorders; Disulfiram; Humans; Naltrexone; Nicotine; Psychotherapy; Psychotropic Drugs; Secondary Prevention; Substance-Related Disorders; Tobacco Use Disorder | 2005 |
Pharmacotherapy treatment in substance-dependent correctional populations: a review.
Topics: Humans; Methadone; Naltrexone; Narcotic Antagonists; Prisoners; Substance-Related Disorders | 2005 |
Evidence-based treatment of geriatric substance abuse.
Topics: Aged; Health Services for the Aged; Humans; Mental Health Services; Naltrexone; Narcotic Antagonists; Substance-Related Disorders | 2005 |
Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches.
Topics: Alcohol Deterrents; Alcoholism; Antipsychotic Agents; Clozapine; Comorbidity; Diagnosis, Dual (Psychiatry); Disulfiram; Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Schizophrenia; Substance-Related Disorders; Treatment Outcome | 2006 |
Substance abuse and schizophrenia: pharmacotherapeutic intervention.
Topics: Acamprosate; Alcohol Deterrents; Antipsychotic Agents; Clozapine; Disulfiram; Drug Interactions; Humans; Naltrexone; Narcotics; Schizophrenia; Substance-Related Disorders; Taurine | 2008 |
[Pharmacotherapy of schizophrenia and comorbid substance use disorder. A systematic review].
Topics: Alcohol Deterrents; Alcoholism; Algorithms; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Clinical Trials as Topic; Comorbidity; Diagnosis, Dual (Psychiatry); Disulfiram; Dose-Response Relationship, Drug; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Naltrexone; Narcotic Antagonists; Schizophrenia; Substance-Related Disorders | 2008 |
Contingency management for treatment of substance abuse.
Topics: Alcoholism; Behavior Therapy; Combined Modality Therapy; Counseling; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Patient Compliance; Reinforcement, Psychology; Substance-Related Disorders; Token Economy; Treatment Outcome | 2006 |
Treatment of alcohol and other drug dependence.
Topics: Alcoholism; Behavior, Addictive; Comorbidity; Humans; Methadone; Naltrexone; Psychotherapy; Substance Withdrawal Syndrome; Substance-Related Disorders; Treatment Outcome | 2007 |
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Biological Psychiatry; Carbamazepine; Disulfiram; Fructose; Health Planning Guidelines; Humans; Naltrexone; Ondansetron; Societies, Scientific; Substance-Related Disorders; Taurine; Topiramate | 2008 |
Contingency management: utility in the treatment of drug abuse disorders.
Topics: Behavior Therapy; Buprenorphine; Cocaine-Related Disorders; Humans; Motivation; Naltrexone; Narcotic Antagonists; Patient Compliance; Receptors, Opioid, mu; Reinforcement, Psychology; Reward; Substance Abuse Detection; Substance Abuse Treatment Centers; Substance-Related Disorders; Treatment Outcome | 2008 |
[Narcotic withdrawal syndrome. Therapeutic methods].
Topics: Acupuncture Therapy; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Analgesia; Brain; Central Nervous System Agents; Clonidine; Endorphins; Humans; Methadone; Naloxone; Naltrexone; Narcotics; Receptors, Opioid; Substance Withdrawal Syndrome; Substance-Related Disorders | 1982 |
[Neuropeptide role in the etiology, pathogenesis and clinical aspects of mental diseases].
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Depressive Disorder; Drug Therapy, Combination; Endorphins; Enkephalins; Humans; Mental Disorders; Naloxone; Naltrexone; Nerve Tissue Proteins; Pituitary Hormones; Psychotropic Drugs; Schizophrenia; Substance-Related Disorders; Vasopressins | 1984 |
The physiology of opiate hedonic effects and the role of opioids in motivated behavior.
Topics: Animals; Conditioning, Operant; Electric Stimulation; Electroshock; Emotions; Endorphins; Feeding Behavior; Humans; Hypothalamus; Medial Forebrain Bundle; Morphine; Motivation; Naloxone; Naltrexone; Narcotics; Rats; Reward; Self Stimulation; Substance-Related Disorders | 1984 |
New insights and treatments: opiate withdrawal and cocaine addiction.
Topics: Brain Chemistry; Clonidine; Cocaine; Dopamine; Humans; Methadone; Naltrexone; Norepinephrine; Substance Withdrawal Syndrome; Substance-Related Disorders | 1984 |
Managing illicit drug use. A practical guide.
Topics: Buprenorphine; Counseling; Disulfiram; Humans; Methadone; Methadyl Acetate; Naltrexone; Psychotherapy; Self-Help Groups; Substance Abuse Treatment Centers; Substance-Related Disorders | 1994 |
Endogenous opioids and excessive alcohol consumption.
Topics: Alcohol Drinking; Animals; Brain; Endorphins; Enkephalins; Ethanol; Hypothalamus; In Vitro Techniques; Naltrexone; Pituitary Gland; RNA; Substance-Related Disorders | 1993 |
[Naltrexone in the therapeutic relation in cases of opioid abuse and dependence].
Topics: Humans; Naltrexone; Narcotics; Opioid-Related Disorders; Physician-Patient Relations; Substance-Related Disorders | 1993 |
What is important in drug misuse treatment?
Topics: Buprenorphine; Clonidine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Substance-Related Disorders; United Kingdom | 1996 |
Recent developments in the pharmacotherapy of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Anti-Anxiety Agents; Buspirone; Disulfiram; Ethanol; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Substance-Related Disorders; Taurine | 1996 |
A risk-benefit assessment of naltrexone in the treatment of alcohol dependence.
Topics: Alcoholism; Dose-Response Relationship, Drug; Drug Interactions; Drug Overdose; Humans; Liver; Naltrexone; Narcotic Antagonists; Neurosecretory Systems; Risk Assessment; Substance-Related Disorders | 1996 |
The integration of pharmacotherapy and nonpharmacotherapy.
Topics: Alcohol Deterrents; Behavior, Addictive; Combined Modality Therapy; Disease Susceptibility; Disulfiram; Drug Interactions; Humans; Naltrexone; Narcotic Antagonists; Patient Acceptance of Health Care; Psychotherapy; Psychotropic Drugs; Substance Withdrawal Syndrome; Substance-Related Disorders; Treatment Outcome | 1997 |
Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Bupropion; Forecasting; Humans; Methadyl Acetate; Naltrexone; Substance-Related Disorders; Taurine; Tobacco Use Disorder | 1999 |
Safe approaches to treating drug addiction.
Topics: Drug Overdose; Family Practice; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Sorption Detoxification; Substance-Related Disorders | 2000 |
Naltrexone and dysphoria: fact or myth?
Topics: Affect; Depression; Humans; Naltrexone; Narcotic Antagonists; Substance-Related Disorders | 2002 |
[The treatment of drug-dependence (author's transl)].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Alcoholism; Amphetamines; Barbiturates; Communication; Drug Tolerance; Female; Halfway Houses; Humans; Male; Methadone; Middle Aged; Morphine Dependence; Motivation; Naltrexone; Personality Disorders; Psychotherapy; Social Control, Formal; Social Control, Informal; Substance-Related Disorders | 1978 |
Recent progress in research on narcotic antagonists.
Topics: Animals; Benzomorphans; Chemical Phenomena; Chemistry; Cyclazocine; Humans; In Vitro Techniques; Models, Biological; Morphinans; Morphine Derivatives; Nalbuphine; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Pentazocine; Receptors, Opioid; Structure-Activity Relationship; Substance-Related Disorders; Thebaine | 1976 |
Clinical pharmacology of narcotic antagonists.
Topics: Animals; Conditioning, Psychological; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Recurrence; Substance Withdrawal Syndrome; Substance-Related Disorders | 1978 |
Pharmacological blocking agents for treating substance abuse.
Topics: Alcoholism; Animals; Behavior Therapy; Disulfiram; Drug Antagonism; Drug Design; Humans; Naltrexone; Narcotic Antagonists; Neurosciences; Opioid-Related Disorders; Rats; Substance-Related Disorders | 1991 |
[Naltrexone].
Topics: Chemical Phenomena; Chemistry; Humans; Naltrexone; Patient Compliance; Substance-Related Disorders | 1989 |
Aversive therapies for substance abuse: do they work?
Topics: Apomorphine; Aversive Therapy; Conditioning, Classical; Desensitization, Psychologic; Electroshock; Emetine; Extinction, Psychological; Humans; Naltrexone; Patient Compliance; Research Design; Substance Withdrawal Syndrome; Substance-Related Disorders; Succinylcholine | 1985 |
Biological evaluation of compounds for their physical dependence potential and abuse liability. X. Drug testing programs of the Committee on Problems of Drug Dependence, Inc. (1986).
Topics: 3,4-Methylenedioxyamphetamine; Animals; Appetite Depressants; Bridged-Ring Compounds; Chemical Phenomena; Chemistry; Meptazinol; N-Methyl-3,4-methylenedioxyamphetamine; Naltrexone; Narcotics; Substance-Related Disorders | 1987 |
Clinical investigations of drug effects in women.
Topics: Buprenorphine; Cocaine; Desipramine; Female; Heroin Dependence; Humans; Male; Naltrexone; Opioid-Related Disorders; Sex Factors; Substance-Related Disorders | 1986 |
32 trial(s) available for naltrexone and Chemical Dependence
| Article | Year |
|---|---|
Acceptability and feasibility of a randomized clinical trial of oral naltrexone vs. placebo for women living with HIV infection: Study design challenges and pilot study results.
Topics: Adult; Alcoholism; Black or African American; Double-Blind Method; Female; HIV Infections; Humans; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Pilot Projects; Substance-Related Disorders | 2017 |
Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol-dependent and polysubstance-dependent individuals.
Topics: Adult; Alcohol Abstinence; Alcohol Deterrents; Alcoholism; Double-Blind Method; Female; Humans; Impulsive Behavior; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Psychomotor Performance; Substance-Related Disorders; Young Adult | 2019 |
Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; CD4 Lymphocyte Count; Delayed-Action Preparations; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebos; Russia; Substance-Related Disorders; Treatment Outcome; Viral Load; Young Adult | 2019 |
The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description.
Topics: Adult; Behavior, Addictive; Biomedical Research; Brain; Cocaine; Cross-Over Studies; Drug Discovery; Ethanol; Female; Humans; Impulsive Behavior; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Neurokinin-1 Receptor Antagonists; Pharmaceutical Preparations; Receptors, Dopamine D3; Receptors, Neurokinin-1; Reward; Secondary Prevention; Substance-Related Disorders | 2015 |
Feasibility, Acceptability, and Tolerability of Targeted Naltrexone for Nondependent Methamphetamine-Using and Binge-Drinking Men Who Have Sex with Men.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Binge Drinking; Condoms; Counseling; Double-Blind Method; Homosexuality, Male; Humans; Male; Methamphetamine; Middle Aged; Naltrexone; Narcotic Antagonists; Placebos; Risk Reduction Behavior; Risk-Taking; Sexual Behavior; Substance-Related Disorders; Unsafe Sex; Young Adult | 2016 |
The impact of treatment condition and the lagged effects of PTSD symptom severity and alcohol use on changes in alcohol craving.
Topics: Adult; Alcoholism; Comorbidity; Craving; Female; Humans; Implosive Therapy; Male; Naltrexone; Severity of Illness Index; Stress Disorders, Post-Traumatic; Substance-Related Disorders; Treatment Outcome | 2016 |
The Effects of Pharmacological Opioid Blockade on Neural Measures of Drug Cue-Reactivity in Humans.
Topics: Adult; Behavior, Addictive; Brain; Brain Mapping; Central Nervous System Stimulants; Cues; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Methamphetamine; Naltrexone; Narcotic Antagonists; Oxygen; Substance-Related Disorders | 2016 |
Acute naltrexone does not remediate fronto-striatal disturbances in alcoholic and alcoholic polysubstance-dependent populations during a monetary incentive delay task.
Topics: Adult; Alcoholism; Corpus Striatum; Delay Discounting; Double-Blind Method; Female; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Reward; Substance-Related Disorders; United Kingdom | 2017 |
Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery.
Topics: Adult; Adult Survivors of Child Adverse Events; Alcoholism; Amygdala; Brain; Case-Control Studies; Cocaine-Related Disorders; Cross-Over Studies; Cues; Double-Blind Method; Female; Functional Neuroimaging; Gyrus Cinguli; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neural Pathways; Opioid-Related Disorders; Prefrontal Cortex; Substance-Related Disorders; Young Adult | 2017 |
Modification of perseverative responding that increased earnings but impeded skill acquisition in a job-skills training program.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Motor Skills Disorders; Naltrexone; Narcotic Antagonists; Rehabilitation, Vocational; Reinforcement, Psychology; Substance-Related Disorders; Therapy, Computer-Assisted; Workplace | 2009 |
Does family history of alcoholism moderate naltrexone's effects on alcohol use?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Family; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Placebos; Sex Characteristics; Substance-Related Disorders; Taurine; Treatment Outcome | 2011 |
Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users.
Topics: Analgesics, Opioid; Cross-Over Studies; Double-Blind Method; Drug Combinations; Drug Interactions; Euphoria; Humans; Injections, Intravenous; Male; Morphine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pain; Pain Measurement; Substance-Related Disorders; Young Adult | 2011 |
Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial.
Topics: Adult; Amphetamine-Related Disorders; Double-Blind Method; Drug Implants; Female; Heroin Dependence; Humans; Male; Naltrexone; Narcotic Antagonists; Substance-Related Disorders; Treatment Outcome; Unsafe Sex | 2012 |
Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cocaine-Related Disorders; Employment; Female; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Dropouts; Reinforcement, Psychology; Substance Abuse, Intravenous; Substance-Related Disorders; Workplace | 2013 |
Naltrexone precipitated opiate withdrawal in methadone addicted human subjects: evidence for noradrenergic hyperactivity.
Topics: Adult; Blood Pressure; Brain; Female; Humans; Kinetics; Male; Methadone; Methoxyhydroxyphenylglycol; Naloxone; Naltrexone; Narcotics; Norepinephrine; Substance Withdrawal Syndrome; Substance-Related Disorders | 1984 |
SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine.
Topics: Adult; Buprenorphine; Female; Gyrus Cinguli; Humans; Male; Naltrexone; Placebos; Regional Blood Flow; Severity of Illness Index; Substance Withdrawal Syndrome; Substance-Related Disorders; Thalamus; Tomography, Emission-Computed, Single-Photon | 1994 |
The efficacy of naltrexone in preventing reabuse of heroin after detoxification.
Topics: Adult; Double-Blind Method; Heroin Dependence; Humans; Male; Middle Aged; Naltrexone; Substance-Related Disorders | 1994 |
Buprenorphine for benzodiazepine-abusing heroin addicts.
Topics: Administration, Sublingual; Benzodiazepines; Buprenorphine; Heroin Dependence; Humans; Methadone; Naltrexone; Substance-Related Disorders | 1994 |
Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans.
Topics: Adult; Buprenorphine; Cocaine; Cross-Over Studies; Double-Blind Method; Drug Interactions; Humans; Hydromorphone; Liver; Male; Naltrexone; Narcotic Antagonists; Narcotics; Respiration; Substance-Related Disorders | 1996 |
Formulation and stability of naltrexone oral liquid for rapid withdrawal from methadone.
Topics: Administration, Oral; Adult; Drug Compounding; Drug Stability; Female; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Substance-Related Disorders | 1997 |
[Preventive therapy of opiate addiction with naltrexone].
Topics: Adolescent; Adult; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Narcotics; Substance-Related Disorders | 1998 |
Predicting treatment response to naltrexone: the influence of craving and family history.
Topics: Adult; Behavior, Addictive; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Prospective Studies; Self-Help Groups; Substance-Related Disorders | 2001 |
Clinical experience with naltrexone in a behavioral research study: an interim report.
Topics: Adult; Behavior; Clinical Trials as Topic; Counseling; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Illicit Drugs; Male; Middle Aged; Motivation; Naloxone; Naltrexone; Outpatient Clinics, Hospital; Patient Compliance; Patient Dropouts; Substance-Related Disorders | 1976 |
Interim report on clinic intake and safety data collected from 17 NIDA-funded naltrexone studies.
Topics: Clinical Trials as Topic; Drug Administration Schedule; Humans; Naloxone; Naltrexone; Patient Dropouts; Statistics as Topic; Substance-Related Disorders | 1976 |
Philosophy and status of NAS CENA study.
Topics: Academies and Institutes; Clinical Trials as Topic; Drug Evaluation; Humans; Naltrexone; Narcotic Antagonists; Patient Compliance; Patient Dropouts; Research Design; Substance-Related Disorders | 1976 |
Varying clinical contexts for administering naltrexone.
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Humans; Male; Middle Aged; Naloxone; Naltrexone; Patient Compliance; Patient Dropouts; Research Design; Statistics as Topic; Substance-Related Disorders; Time Factors | 1976 |
Patient response to naltrexone: issues of acceptance, treatment effects, and frequency of administration.
Topics: Adult; Clinical Trials as Topic; Drug Evaluation; Heroin Dependence; Humans; Male; Naloxone; Naltrexone; Patient Acceptance of Health Care; Patient Dropouts; Substance-Related Disorders; Time Factors | 1976 |
Comments and findings from a naltrexone double blind study.
Topics: Clinical Trials as Topic; Humans; Methadone; Naloxone; Naltrexone; Research Design; Statistics as Topic; Substance-Related Disorders | 1976 |
Clinical experiences with naltrexone in 370 detoxified addicts.
Topics: Clinical Trials as Topic; Cyclazocine; Drug Administration Schedule; Humans; Methadone; Naloxone; Naltrexone; Patient Compliance; Physicians; Placebos; Research Personnel; Substance-Related Disorders | 1976 |
Narcotic antagonist treatment of the criminal justice patient-institutional vs outpatient-including a 24 hour detox naltrexone induction regimen with oral medication.
Topics: Adolescent; Adult; Clinical Trials as Topic; Counseling; Drug Administration Schedule; Drug Evaluation; Female; Halfway Houses; Humans; Male; Middle Aged; Naloxone; Naltrexone; Narcotic Antagonists; Outpatient Clinics, Hospital; Prisoners; Rehabilitation, Vocational; Research Design; Social Adjustment; Substance-Related Disorders | 1976 |
Use of narcotic antagonists (naltrexone) in an addiction treatment program.
Topics: Adolescent; Adult; Attitude; Clinical Trials as Topic; Drug Evaluation; Humans; Male; Middle Aged; Naloxone; Naltrexone; Patient Compliance; Personality Inventory; Self Medication; Substance-Related Disorders; Time Factors | 1976 |
Human pharmacology and abuse potential of nalmefene.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Male; Morphine; Naltrexone; Narcotic Antagonists; Substance-Related Disorders | 1991 |
153 other study(ies) available for naltrexone and Chemical Dependence
| Article | Year |
|---|---|
Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
Topics: Animals; Aorta, Thoracic; Cocaine; Cyclic AMP; Electric Stimulation; Guinea Pigs; Humans; Ileum; In Vitro Techniques; Male; Mice; Muscle, Smooth; Opioid-Related Disorders; Rats; Receptors, Dopamine; Receptors, Opioid; Receptors, Serotonin; Substance-Related Disorders | 1998 |
Substance Use Withdrawal and Detox Strategies That Work.
Topics: Antisocial Personality Disorder; Health Personnel; Humans; Mental Health Services; Naltrexone; Substance-Related Disorders | 2021 |
The Setting-Intervention Fit of Nine Evidence-Based Interventions for Substance Use Disorders Within HIV Service Organizations Across the United States: Results of a National Stakeholder-Engaged Real-Time Delphi Study.
Topics: Buprenorphine; Delphi Technique; Evidence-Based Medicine; HIV Infections; Humans; Naltrexone; Substance-Related Disorders; United States | 2022 |
Defining a recovery-oriented cascade of care for opioid use disorder: A community-driven, statewide cross-sectional assessment.
Topics: Analgesics, Opioid; Clinical Protocols; Cross-Sectional Studies; Drug Overdose; Humans; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Rhode Island; Risk Assessment; Risk Factors; Social Work; Stakeholder Participation; Substance-Related Disorders; United States | 2019 |
A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use.
Topics: Acamprosate; Addiction Medicine; Adult; Aged; Alcohol Deterrents; Alcoholism; Buprenorphine; Emergency Service, Hospital; Female; Gabapentin; Humans; Male; Middle Aged; Naltrexone; Ontario; Opioid-Related Disorders; Patient Acceptance of Health Care; Primary Health Care; Referral and Consultation; Socioeconomic Factors; Substance Abuse Treatment Centers; Substance-Related Disorders; Time Factors; Young Adult | 2020 |
The Persistent Challenge of Developing Addiction Pharmacotherapies.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bupropion; Central Nervous System Stimulants; Cocaine-Related Disorders; Drug Therapy; Humans; Naltrexone; Narcotic Antagonists; Nicotinic Agonists; Smoking Cessation Agents; Substance-Related Disorders; Varenicline | 2021 |
Samidorphan, an opioid receptor antagonist, attenuates drug-induced increases in extracellular dopamine concentrations and drug self-administration in male Wistar rats.
Topics: Amphetamine; Animals; Cocaine; Dopamine; Ethanol; Humans; Male; Microdialysis; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Oxycodone; Rats; Rats, Wistar; Receptors, Opioid; Receptors, Opioid, mu; Self Administration; Substance-Related Disorders | 2021 |
Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Female; Humans; Middle Aged; Naltrexone; Substance-Related Disorders | 2021 |
Screening, treatment initiation, and referral for substance use disorders.
Topics: Alcoholism; Buprenorphine; Emergency Service, Hospital; Humans; Mass Screening; Motivational Interviewing; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Referral and Consultation; Substance-Related Disorders; Tobacco Use Disorder | 2017 |
The Role of Pleasure Neurobiology and Dopamine in Mental Health Disorders.
Topics: Behavior, Addictive; Brain; Dopamine; Humans; Mental Disorders; Naltrexone; Narcotic Antagonists; Neurobiology; Off-Label Use; Pleasure; Psychiatric Nursing; Substance-Related Disorders | 2017 |
Effectiveness of extended release naltrexone to reduce alcohol cravings and use behaviors during treatment and at follow-up.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Craving; Delayed-Action Preparations; Female; Follow-Up Studies; Humans; Male; Naltrexone; Substance-Related Disorders | 2018 |
Therapeutic challenges in comorbid obsessive compulsive disorder with substance use.
Topics: Adrenergic alpha-2 Receptor Agonists; Clonazepam; Clonidine; Combined Modality Therapy; Fluoxetine; GABA Modulators; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obsessive-Compulsive Disorder; Relaxation Therapy; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders | 2018 |
Naltrexone maintenance fails to alter amphetamine effects on intracranial self-stimulation in rats.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Cocaine; Deep Brain Stimulation; Dose-Response Relationship, Drug; Male; Medial Forebrain Bundle; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Rats; Rats, Sprague-Dawley; Self Stimulation; Substance-Related Disorders | 2018 |
Tackling addiction in primary care.
Topics: Alcoholism; Buprenorphine; Drug Combinations; Humans; Illicit Drugs; Interdisciplinary Communication; Intersectoral Collaboration; Mass Screening; Minnesota; Naloxone; Naltrexone; Opioid-Related Disorders; Prescription Drugs; Primary Health Care; Referral and Consultation; Substance-Related Disorders | 2017 |
Long-acting injectable depot naltrexone use in the Veterans' Health Administration: a national study.
Topics: Alcohol-Related Disorders; Comorbidity; Delayed-Action Preparations; Diagnosis, Dual (Psychiatry); Drug Prescriptions; Drug Utilization; Female; Hospitalization; Humans; Logistic Models; Male; Mental Disorders; Mental Health Services; Middle Aged; Multivariate Analysis; Naltrexone; Narcotic Antagonists; Psychiatric Department, Hospital; Rural Population; Socioeconomic Factors; Substance-Related Disorders; United States; United States Department of Veterans Affairs; Urban Population; Veterans | 2014 |
Adoption and diffusion of evidence-based addiction medications in substance abuse treatment.
Topics: Alcohol Deterrents; Buprenorphine; Diffusion of Innovation; Disulfiram; Evidence-Based Medicine; Health Services Research; Humans; Naltrexone; Narcotic Antagonists; Practice Patterns, Physicians'; Substance Abuse Treatment Centers; Substance-Related Disorders; Surveys and Questionnaires; United States | 2014 |
Abuse-related effects of µ-opioid analgesics in an assay of intracranial self-stimulation in rats: modulation by chronic morphine exposure.
Topics: Analgesics, Opioid; Analysis of Variance; Animals; Conditioning, Operant; Disease Models, Animal; Dose-Response Relationship, Drug; Electric Stimulation; Electrodes, Implanted; Male; Medial Forebrain Bundle; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Self Administration; Self Stimulation; Substance-Related Disorders | 2013 |
Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects.
Topics: Analgesics; Animals; Arrestins; Avoidance Learning; beta-Arrestins; Calcium; Drug Tolerance; HEK293 Cells; Humans; Indoles; Mice; Naltrexone; Protein Multimerization; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Stereoisomerism; Structure-Activity Relationship; Substance-Related Disorders | 2014 |
Effects of the NOP agonist SCH221510 on producing and attenuating reinforcing effects as measured by drug self-administration in rats.
Topics: Animals; Azabicyclo Compounds; Benzimidazoles; Dose-Response Relationship, Drug; Male; Naltrexone; Narcotic Antagonists; Nociceptin Receptor; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Receptors, Opioid, mu; Reinforcement, Psychology; Remifentanil; Self Administration; Substance-Related Disorders | 2014 |
Chorionic morphine, naltrexone and pentoxifylline effect on hypophyso-gonadal hormones of male rats.
Topics: Animals; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Gonadotropins, Pituitary; Male; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Pentoxifylline; Phosphodiesterase Inhibitors; Rats; Rats, Wistar; Reproduction; Substance-Related Disorders; Testosterone | 2015 |
Pharmacotherapy: Quest for the quitting pill.
Topics: Animals; Behavior, Addictive; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Clinical Trials as Topic; Cocaine-Related Disorders; Counseling; Dopamine; Drug Discovery; Drug Industry; Humans; Ibogaine; Lobeline; Molecular Targeted Therapy; Naloxone; Naltrexone; Oligopeptides; Opioid-Related Disorders; Pleasure; Rats; Receptors, Nicotinic; Reward; Substance-Related Disorders; Tobacco Use Disorder; Vaccines; Vesicular Monoamine Transport Proteins | 2015 |
Access to Addiction Pharmacotherapy in Private Health Plans.
Topics: Acamprosate; Buprenorphine; Cost Sharing; Evidence-Based Practice; Formularies as Topic; Health Services Accessibility; Humans; Insurance, Health; Naltrexone; Substance-Related Disorders; Surveys and Questionnaires; Taurine; United States | 2016 |
Rearing environment differentially modulates cocaine self-administration after opioid pretreatment: A behavioral economic analysis.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Cocaine; Economics, Behavioral; Environment; Male; Morphine; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Self Administration; Substance-Related Disorders; Time Factors | 2016 |
Functional modulation on macrophage by low dose naltrexone (LDN).
Topics: Alcoholism; Analgesics, Opioid; Animals; Cells, Cultured; Humans; Immunologic Factors; Interleukin-12; Lymphocyte Activation; Macrophage Activation; Macrophages; Mice; Mice, Inbred BALB C; Naltrexone; Nitric Oxide; Receptors, IgG; Receptors, Opioid, delta; Substance-Related Disorders; Tumor Necrosis Factor-alpha | 2016 |
Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals.
Topics: Adult; Alcohol Deterrents; Alcoholism; Brain; Female; Functional Neuroimaging; Healthy Volunteers; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Neural Pathways; Substance-Related Disorders; Young Adult | 2018 |
The Los Angeles County hub-and-provider network for promoting the sustained use of extended-release naltrexone (XR-NTX) in Los Angeles County (2010-2015).
Topics: Adult; Delayed-Action Preparations; Female; Health Services Accessibility; Humans; Los Angeles; Male; Medication Adherence; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Program Development; Quality of Life; Substance-Related Disorders | 2018 |
Insufficient information in drug-related hospital morbidity study.
Topics: Hospitals; Humans; Information Dissemination; Medication Errors; Methadone; Naltrexone; Narcotic Antagonists; Substance-Related Disorders | 2009 |
The use of depot naltrexone under legal coercion: the case for caution.
Topics: Coercion; Delayed-Action Preparations; Humans; Naltrexone; Narcotic Antagonists; Personal Autonomy; Substance-Related Disorders | 2008 |
The importance of taking a history of over-the-counter medication use: a brief review and case illustration of "PRN" antihistamine dependence in a hospitalized adolescent.
Topics: Adolescent; Female; Histamine H1 Antagonists; Humans; Hydroxyzine; Medical History Taking; Naltrexone; Narcotic Antagonists; Nonprescription Drugs; Substance-Related Disorders | 2010 |
Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation.
Topics: Acamprosate; Alcohol Deterrents; Buprenorphine; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Patient Education as Topic; Substance Abuse Treatment Centers; Substance-Related Disorders; Taurine; United States | 2011 |
Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approach.
Topics: Attitude of Health Personnel; Counseling; Cross-Sectional Studies; Female; Humans; Injections; Male; Middle Aged; Multilevel Analysis; Naltrexone; Narcotic Antagonists; Substance-Related Disorders; Tablets; United States | 2011 |
Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions.
Topics: Adult; Buprenorphine; Crime; Criminal Law; Data Collection; Female; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Pregnancy; Pregnancy Complications; Prisons; Substance-Related Disorders; Young Adult | 2012 |
Sustained-release opiate blockers for treating heroin and amphetamine dependence.
Topics: Female; Humans; Male; Naltrexone; Narcotic Antagonists; Substance-Related Disorders | 2012 |
Pharmacotherapy for adolescent alcohol use disorder.
Topics: Acamprosate; Adolescent; Alcohol-Related Disorders; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Central Nervous System Stimulants; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders; Disulfiram; Humans; Naltrexone; Substance Withdrawal Syndrome; Substance-Related Disorders; Taurine | 2012 |
Discrimination of a single dose of morphine followed by naltrexone: substitution of other agonists for morphine and other antagonists for naltrexone in a rat model of acute dependence.
Topics: Acute Disease; Analgesics, Opioid; Animals; Disease Models, Animal; Fentanyl; Male; Methadone; Morphine; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Substance-Related Disorders | 2003 |
Enhanced binding of nor-binaltorphimine to kappa-opioid receptors in rats dependent on butorphanol.
Topics: Animals; Brain; Butorphanol; Dose-Response Relationship, Drug; Male; Naltrexone; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Substance Withdrawal Syndrome; Substance-Related Disorders | 2003 |
Understanding US addiction physicians' low rate of naltrexone prescription.
Topics: Data Collection; Drug Prescriptions; Humans; Logistic Models; Multivariate Analysis; Naltrexone; Patient Compliance; Physicians; Substance-Related Disorders; United States | 2003 |
Health for life. Addiction: how to break the chain.
Topics: Behavior, Addictive; Brain; Dopamine Agonists; Humans; Naltrexone; Narcotic Antagonists; Reinforcement, Psychology; Reward; Substance-Related Disorders; United States | 2005 |
Pathological gambling: focusing on the addiction, not the activity.
Topics: Behavior, Addictive; Gambling; Humans; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Receptors, Opioid; Substance-Related Disorders; Treatment Outcome | 2006 |
Use of pharmacotherapies for the management of addictive behaviours in Australian clinical practice.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Australia; Bupropion; Dopamine Uptake Inhibitors; Female; Health Care Surveys; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Substance-Related Disorders; Taurine; Tobacco Use Disorder | 2006 |
Naltrexone in patients with bipolar disorder and alcohol dependence.
Topics: Adult; Alcoholism; Bipolar Disorder; Comorbidity; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Pilot Projects; Psychiatric Status Rating Scales; Psychotropic Drugs; Secondary Prevention; Substance Abuse Detection; Substance-Related Disorders; Treatment Outcome | 2006 |
Noradrenaline is necessary for the hedonic properties of addictive drugs.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Appetitive Behavior; Benzazepines; Biphenyl Compounds; Bupropion; Carbidopa; Cocaine; Dopamine beta-Hydroxylase; Dopamine Uptake Inhibitors; Droxidopa; Female; Genotype; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Knockout; Morphine; Naltrexone; Narcotic Antagonists; Neurokinin-1 Receptor Antagonists; Norepinephrine; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D1; Reward; Substance-Related Disorders | 2006 |
New challenges and opportunities in managing substance abuse in Malaysia.
Topics: Buprenorphine; HIV Infections; Humans; Malaysia; Mental Health Services; Naltrexone; Narcotics; Prevalence; Registries; Risk Factors; Risk-Taking; Substance-Related Disorders | 2006 |
The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters.
Topics: Community Mental Health Centers; Disulfiram; Humans; Multivariate Analysis; Naltrexone; Narcotic Antagonists; National Institutes of Health (U.S.); Regression Analysis; Substance Abuse Detection; Substance-Related Disorders; Treatment Outcome; United States | 2007 |
Schizophrenia and co-occurring substance use disorder.
Topics: Acamprosate; Adult; Alcohol-Related Disorders; Antipsychotic Agents; Comorbidity; Diagnosis, Dual (Psychiatry); Disulfiram; Humans; Ill-Housed Persons; Male; Naltrexone; Schizophrenia; Substance-Related Disorders; Taurine | 2007 |
Brain scans, genes provide addiction clues.
Topics: Benzhydryl Compounds; Brain; Brain Chemistry; Central Nervous System Agents; Humans; Modafinil; Monoamine Oxidase Inhibitors; Naltrexone; Positron-Emission Tomography; Substance-Related Disorders | 2007 |
Enhanced sensitivity to naltrexone-induced drinking suppression of fluid intake and sucrose consumption in maternally separated rats.
Topics: Animals; Brain; Drinking; Female; Food Preferences; Male; Models, Animal; Naltrexone; Narcotic Antagonists; Opioid Peptides; Pregnancy; Rats; Rats, Long-Evans; Reward; Sex Characteristics; Solutions; Stress, Psychological; Substance-Related Disorders; Sucrose | 2007 |
Opioid overdose deaths can occur in patients with naltrexone implants.
Topics: Analgesics, Opioid; Drug Implants; Drug Overdose; Heroin; Humans; Naltrexone; Narcotic Antagonists; Substance-Related Disorders | 2007 |
Opioid overdose deaths can occur in patients with naltrexone implants.
Topics: Analgesics, Opioid; Autopsy; Drug Implants; Drug Monitoring; Drug Overdose; Humans; Naltrexone; Narcotic Antagonists; Substance-Related Disorders | 2007 |
Opioid overdose deaths can occur in patients with naltrexone implants.
Topics: Analgesics, Opioid; Drug Implants; Drug Overdose; Humans; Naltrexone; Narcotic Antagonists; Substance-Related Disorders; Treatment Outcome | 2007 |
Opioid overdose deaths can occur in patients with naltrexone implants.
Topics: Analgesics, Opioid; Drug Implants; Drug Overdose; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Selection; Substance-Related Disorders | 2007 |
Opioid overdose deaths can occur in patients with naltrexone implants.
Topics: Analgesics, Opioid; Cause of Death; Drug Implants; Drug Overdose; Humans; Naltrexone; Narcotic Antagonists; Substance-Related Disorders | 2007 |
Pharmacotherapeutic environments for substance use disorders.
Topics: Ambulatory Care; Buprenorphine; Cognitive Behavioral Therapy; Delayed-Action Preparations; Family Practice; Heroin Dependence; Hospitalization; Humans; Methadone; Naltrexone; Office Visits; Opioid-Related Disorders; Secondary Prevention; Substance-Related Disorders | 2007 |
Behavioral economic analysis of drug preference using multiple choice procedure data.
Topics: Choice Behavior; Economics; Fentanyl; Fluoxetine; Hallucinogens; Humans; Hydromorphone; Injections, Intramuscular; Methadone; Models, Psychological; Motivation; N-Methyl-3,4-methylenedioxyamphetamine; Naltrexone; Narcotics; Psychotropic Drugs; Recreation; Selective Serotonin Reuptake Inhibitors; Substance Abuse, Intravenous; Substance-Related Disorders | 2008 |
Organizational-level predictors of adoption across time: naltrexone in private substance-use disorders treatment centers.
Topics: Culture; Drug Utilization; Humans; Leadership; Naltrexone; Narcotic Antagonists; Private Sector; Substance Abuse Treatment Centers; Substance-Related Disorders | 2007 |
A categorical typology of naltrexone-adopting private substance abuse treatment centers.
Topics: Humans; Naltrexone; Private Sector; Substance Abuse Treatment Centers; Substance-Related Disorders | 2008 |
Toward a rational selection of treatment for addiction.
Topics: Alleles; Buprenorphine; Genetic Variation; Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu; Substance-Related Disorders | 2007 |
Drug addiction: a critical problem calling for novel solutions.
Topics: Benzazepines; Buprenorphine; Bupropion; Chronic Disease; Financing, Government; Genetic Testing; Harm Reduction; Humans; Marijuana Smoking; Naltrexone; Narcotic Antagonists; Prevalence; Privacy; Quinoxalines; Receptors, Nicotinic; Recurrence; Risk-Taking; Smoking; Smoking Cessation; Smoking Prevention; Social Environment; Substance-Related Disorders; Varenicline | 2008 |
Emerging concepts concerning drug abuse.
Topics: Adolescent; Adult; Animals; Cats; Conditioning, Psychological; Cyclazocine; Dogs; Euphoria; Guinea Pigs; Homeostasis; Humans; Models, Biological; Mood Disorders; Morphine Dependence; Naltrexone; Rats; Receptors, Opioid; Substance-Related Disorders | 1980 |
Antagonism by chlornaltrexamine of some effects of delta 9-tetrahydrocannabinol in rats.
Topics: Analgesia; Animals; Dronabinol; Drug Tolerance; Humans; Hypothermia; Male; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Nitrogen Mustard Compounds; Rats; Receptors, Opioid; Substance-Related Disorders | 1981 |
Abstinence treatments for opiate addicts: therapeutic community or naltrexone?
Topics: Follow-Up Studies; Humans; Male; Naloxone; Naltrexone; Opioid-Related Disorders; Substance-Related Disorders; Therapeutic Community | 1984 |
Effects of b-FNA in drug-naive and morphine-dependent rhesus monkeys.
Topics: Animals; Macaca mulatta; Morphine; Naltrexone; Substance-Related Disorders; Time Factors | 1984 |
Addiction and anesthesiology.
Topics: American Medical Association; Anesthesiology; Disability Evaluation; Humans; Licensure, Medical; Naltrexone; Occupational Diseases; Risk; Self-Help Groups; Substance-Related Disorders; United States | 1984 |
Clonidine hydrochloride detoxification from methadone treatments: the value of naltrexone aftercare.
Topics: Adolescent; Clonidine; Humans; Inactivation, Metabolic; Methadone; Naloxone; Naltrexone; Opium; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors | 1981 |
Tolerance to and physical dependence on N-allylnormetazocine (NANM) in chronic spinal dogs.
Topics: Animals; Body Temperature; Decerebrate State; Dogs; Drug Tolerance; Eating; Female; Humans; Naltrexone; Phenazocine; Pulse; Pupil; Reflex; Substance-Related Disorders | 1980 |
Multiple family therapy and naltrexone in the treatment of opiate dependence.
Topics: Adolescent; Adult; Data Collection; Family Therapy; Female; Humans; Male; Middle Aged; Naloxone; Naltrexone; Narcotics; Retrospective Studies; Statistics as Topic; Substance-Related Disorders | 1981 |
Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment.
Topics: Analgesia; Analgesics, Opioid; Animals; Behavior, Animal; Culture Techniques; Dose-Response Relationship, Drug; Drug Interactions; Drug Tolerance; Electrophysiology; Ganglia, Spinal; Mice; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Neurons, Afferent; Pain Measurement; Substance Withdrawal Syndrome; Substance-Related Disorders | 1995 |
Behavioral and biochemical evidence of opioidergic involvement in cocaine sensitization.
Topics: Adenylyl Cyclases; Animals; Cocaine; Drug Tolerance; Male; Motor Activity; Naltrexone; Nucleus Accumbens; Opioid Peptides; Rats; Rats, Wistar; Receptors, Dopamine D1; Substance-Related Disorders | 1995 |
[Role of LAAM, methadone and naltrexone in the care of opiate dependence. Experience in Portugal].
Topics: Drug Administration Schedule; Female; Heroin Dependence; Humans; Male; Methadone; Methadyl Acetate; Naltrexone; Narcotics; Patient Compliance; Portugal; Substance-Related Disorders; Time Factors | 1994 |
The kappa-opioid receptor agonist U50,488H induces acute physical dependence in guinea-pigs.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Opioid; Animals; Behavior, Animal; Female; Guinea Pigs; Ileum; In Vitro Techniques; Male; Morphine Dependence; Motor Activity; Muscle Contraction; Muscle, Smooth; Naloxone; Naltrexone; Pyrrolidines; Receptors, Opioid, kappa; Substance Withdrawal Syndrome; Substance-Related Disorders | 1993 |
Effects of naltrexone pellet implantation on morphine tolerance and physical dependence in the rat.
Topics: Analgesia; Animals; Body Temperature; Dose-Response Relationship, Drug; Drug Implants; Drug Interactions; Drug Tolerance; Male; Morphine; Naltrexone; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors; Weight Loss | 1994 |
Lack of involvement of delta-1 opioid receptors in the development of physical dependence on morphine in mice.
Topics: Affinity Labels; Animals; Diarrhea; Enkephalin, Leucine-2-Alanine; Injections, Intraventricular; Injections, Spinal; Isothiocyanates; Male; Mice; Morphine; Naloxone; Naltrexone; Receptors, Opioid, delta; Substance-Related Disorders | 1994 |
Involvement of kappa-opioid receptors in opioid dependence/withdrawal: studies using butorphanol.
Topics: Animals; Butorphanol; Injections, Intraventricular; Male; Naloxone; Naltrexone; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Substance Withdrawal Syndrome; Substance-Related Disorders | 1994 |
Dependence on tramadol.
Topics: Adult; Drug Tolerance; Euphoria; Female; Humans; Naltrexone; Seizures; Substance Withdrawal Syndrome; Substance-Related Disorders; Tramadol | 1993 |
Antinociceptive effect of dihydroetorphine and its tolerance/dependence liability in mice.
Topics: Analgesics; Animals; Body Weight; Drug Tolerance; Etorphine; Male; Mice; Mice, Inbred Strains; Morphine; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Pain Measurement; Substance-Related Disorders | 1993 |
Effects of nor-binaltorphimine on butorphanol dependence.
Topics: Animals; Benzeneacetamides; Body Temperature; Body Weight; Butorphanol; Diarrhea; Down-Regulation; Drug Administration Schedule; Escape Reaction; Male; Naltrexone; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Substance Withdrawal Syndrome; Substance-Related Disorders; Tremor | 1993 |
Involvement of delta 2 opioid receptors in acute dependence on morphine in mice.
Topics: Animals; Drug Interactions; Enkephalin, Leucine; Isothiocyanates; Male; Mice; Morphine; Naltrexone; Receptors, Opioid, delta; Substance-Related Disorders; Thiocyanates | 1993 |
Involvement of delta-opioid receptors in physical dependence on butorphanol.
Topics: Animals; Butorphanol; Enkephalin, D-Penicillamine (2,5)-; Enkephalins; Male; Naltrexone; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Substance-Related Disorders | 1993 |
Effects of chronic treatment with methadone and naltrexone on sleep in addicts.
Topics: Adult; Analgesics, Opioid; Female; Heroin; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Sleep; Substance-Related Disorders | 1996 |
Misuse of naltrexone.
Topics: Adult; Alcoholism; Humans; Male; Naltrexone; Schizophrenia, Paranoid; Substance-Related Disorders | 1996 |
Isradipine in combination with naltrexone as a medicine for treating cocaine abuse.
Topics: Animals; Calcium Channel Blockers; Cocaine; Drug Therapy, Combination; Electric Stimulation; Isradipine; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Substance-Related Disorders | 1997 |
Naltrexone treatment of hallucinogen persisting perception disorder.
Topics: Adult; Child; Humans; Lysergic Acid Diethylamide; Male; Naltrexone; Perceptual Disorders; Substance-Related Disorders; Suicide; Visual Perception | 1997 |
Managing pain in addicted patients.
Topics: Alcoholism; Analgesics; Heroin Dependence; Humans; Naltrexone; Narcotic Antagonists; Pain; Recurrence; Substance-Related Disorders | 1997 |
Increased release of excitatory amino acids in rat locus coeruleus in kappa-opioid agonist dependent rats precipitated by nor-binaltorphimine.
Topics: Animals; Benzeneacetamides; Butorphanol; Drug Evaluation, Preclinical; Excitatory Amino Acids; Locus Coeruleus; Male; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Receptors, Opioid, mu; Substance Withdrawal Syndrome; Substance-Related Disorders | 1997 |
Evidence for roles of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine.
Topics: Animals; Corpus Striatum; Dopamine; Female; Ibogaine; Morphine; Motor Activity; N-Methylaspartate; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid, kappa; Self Administration; Substance-Related Disorders | 1997 |
Addiction medicine.
Topics: Alcoholism; Behavior Therapy; Clinical Medicine; Humans; Liver Transplantation; Naltrexone; Narcotic Antagonists; Substance-Related Disorders | 1997 |
Differential effects of naltrindole on morphine-induced tolerance and physical dependence in rats.
Topics: Animals; Drug Tolerance; Female; Male; Morphine; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Substance-Related Disorders | 1997 |
Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice.
Topics: Administration, Oral; Analgesics, Opioid; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Tolerance; Etorphine; Infusions, Parenteral; Male; Mice; Mice, Inbred Strains; Morphine; Motor Activity; Naltrexone; Narcotic Antagonists; Narcotics; Nociceptors; Substance Withdrawal Syndrome; Substance-Related Disorders | 1997 |
Effects of kappa opioids on cocaine self-administration by rhesus monkeys.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Circadian Rhythm; Cocaine; Dose-Response Relationship, Drug; Ethylketocyclazocine; Female; Macaca mulatta; Male; Naloxone; Naltrexone; Pyrrolidines; Receptors, Opioid, kappa; Self Administration; Substance-Related Disorders | 1997 |
Outpatient non-opioid detoxification for opioid withdrawal. Who is likely to benefit?
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Ambulatory Care Facilities; Clonidine; Female; GABA Modulators; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Oxazepam; Retrospective Studies; Substance Withdrawal Syndrome; Substance-Related Disorders; Treatment Outcome | 1997 |
Rapid opiate detoxification. Assessment is needed to exclude certain patients before detoxification.
Topics: Adrenergic alpha-Agonists; Clonidine; Humans; Naltrexone; Narcotic Antagonists; Narcotics; Substance Withdrawal Syndrome; Substance-Related Disorders | 1997 |
Persistent analgesia in former opiate addicts is resistant to blockade of endogenous opioids.
Topics: Adult; Analgesia; Drug Tolerance; Female; Heroin; Humans; Inactivation, Metabolic; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pain Threshold; Perceptual Disorders; Receptors, Opioid; Substance-Related Disorders | 1997 |
Drug abuse and therapy.
Topics: Alcohol-Related Disorders; Animals; Anti-Anxiety Agents; Antipsychotic Agents; Clinical Trials as Topic; Drug Industry; Humans; Naltrexone; National Institutes of Health (U.S.); Substance-Related Disorders; United States | 1998 |
Use of the Internet for addiction education. Combining network therapy with pharmacotherapy.
Topics: Combined Modality Therapy; Computer Communication Networks; Health Education; Humans; Mental Health; Naltrexone; Narcotic Antagonists; Psychotherapy; Substance-Related Disorders; Surveys and Questionnaires | 1998 |
A combination of isradipine and naltrexone blocks cocaine's enhancement of a cocaine place preference.
Topics: Animals; Calcium Channel Blockers; Cocaine; Conditioning, Operant; Dose-Response Relationship, Drug; Isradipine; Male; Mental Recall; Naltrexone; Narcotic Antagonists; Narcotics; Rats; Rats, Sprague-Dawley; Substance-Related Disorders | 1998 |
MU-opioid receptor-knockout mice: role of mu-opioid receptor in morphine mediated immune functions.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Binding, Competitive; Disease Models, Animal; Drug Implants; Exons; Gene Targeting; Immune System; Immunosuppression Therapy; Interleukin-2; Ligands; Macrophage Activation; Macrophages, Peritoneal; Mice; Mice, Knockout; Mitogens; Morphine; Naltrexone; Organ Size; Phagocytosis; Receptors, Opioid, mu; Spleen; Substance-Related Disorders; Thymidine; Thymus Gland; Tumor Necrosis Factor-alpha | 1998 |
[Interactions between naltrexone, an opioid antagonist, and opioids administered during general anesthesia].
Topics: Alcoholism; Analgesics, Opioid; Anesthesia, Intravenous; Anesthetics, Intravenous; Drug Interactions; Female; Humans; Hysterectomy; Middle Aged; Naltrexone; Narcotic Antagonists; Substance-Related Disorders; Sufentanil | 1999 |
The importance of the number of NMDA receptors in the development of supersensitivity or tolerance to and dependence on morphine.
Topics: Analgesics, Opioid; Animals; Brain; Dizocilpine Maleate; Drug Tolerance; Excitatory Amino Acid Antagonists; Kinetics; Male; Morphine; Naltrexone; Narcotic Antagonists; Pain Measurement; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Substance-Related Disorders | 1999 |
Acute opioid but not benzodiazepine dependence in rats responding for intracranial self-stimulation.
Topics: Animals; Benzodiazepines; Brain; Diazepam; Dose-Response Relationship, Drug; Flumazenil; Male; Morphine; Naltrexone; Opioid-Related Disorders; Rats; Rats, Sprague-Dawley; Reinforcement Schedule; Self Stimulation; Substance-Related Disorders | 2000 |
Preclinical study of an oral controlled release naltrexone complex in mice.
Topics: Administration, Oral; Animals; Delayed-Action Preparations; Drug Administration Schedule; Male; Mice; Naltrexone; Narcotic Antagonists; Substance-Related Disorders | 2000 |
Naltrexone treatment of dementia with severe self-injurious behaviors: a single case study.
Topics: Adult; Dementia; Humans; Male; Naltrexone; Narcotic Antagonists; Nursing Homes; Self-Injurious Behavior; Social Behavior; Substance-Related Disorders; Treatment Outcome | 2000 |
Addiction medicine for the primary care physician.
Topics: Acamprosate; Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Antidepressive Agents, Tricyclic; Disulfiram; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Primary Health Care; Recurrence; Risk Factors; Severity of Illness Index; Substance-Related Disorders; Taurine; Treatment Outcome | 2001 |
Antagonism of the antinociceptive and discriminative stimulus effects of heroin and morphine by 3-methoxynaltrexone and naltrexone in rhesus monkeys.
Topics: Analgesics; Analgesics, Opioid; Animals; Cues; Discrimination Learning; Discrimination, Psychological; Dose-Response Relationship, Drug; Heroin; Hot Temperature; Kinetics; Macaca mulatta; Male; Morphine; Naltrexone; Narcotic Antagonists; Pain Measurement; Substance-Related Disorders | 2002 |
Adoption and implementation of new technologies in substance abuse treatment.
Topics: Humans; Leadership; Managed Care Programs; Naltrexone; Narcotic Antagonists; Substance Abuse Treatment Centers; Substance-Related Disorders; Technology Transfer | 2002 |
Naltrexone in a behavioral treatment program.
Topics: Behavior; Conditioning, Psychological; Extinction, Psychological; Humans; Hydromorphone; Injections; Naloxone; Naltrexone; Remission, Spontaneous; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors | 1976 |
Naltrexone-induced hypothermia in the rat.
Topics: Animals; Body Temperature Regulation; Dose-Response Relationship, Drug; Humans; Hypothermia; Morphine; Naloxone; Naltrexone; Placebos; Rats; Receptors, Opioid; Substance Withdrawal Syndrome; Substance-Related Disorders | 1976 |
A history of the development of narcotic antagonists for the treatment of narcotic addiction.
Topics: Animals; Cyclazocine; Drug Tolerance; Euphoria; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Receptors, Opioid; Substance-Related Disorders | 1978 |
Update of naltrexone treatment.
Topics: Adult; Conditioning, Psychological; Female; Humans; Male; Methadone; Naloxone; Naltrexone; Narcotics; Receptors, Opioid; Social Adjustment; Substance Withdrawal Syndrome; Substance-Related Disorders | 1978 |
Naltrexone in the treatment of opiate dependence.
Topics: Adolescent; Adult; Follow-Up Studies; Forecasting; Heroin Dependence; Humans; Male; Methadone; Naloxone; Naltrexone; Narcotics; New York City; Psychotherapy; Receptors, Opioid; Recurrence; Substance Withdrawal Syndrome; Substance-Related Disorders | 1978 |
The development of sustained action preparations of narcotic antagonists.
Topics: Animals; Delayed-Action Preparations; Drug Implants; Humans; Naloxone; Naltrexone; Narcotics; Receptors, Opioid; Research Design; Substance-Related Disorders | 1978 |
Clinical outcome with naltrexone.
Topics: Follow-Up Studies; Humans; Male; Naloxone; Naltrexone; Substance-Related Disorders; Time Factors | 1978 |
The pharmacology of thebaine in the chronic spinal dog.
Topics: Animals; Dogs; Humans; Naloxone; Naltrexone; Spinal Cord; Substance Withdrawal Syndrome; Substance-Related Disorders; Thebaine; Time Factors | 1978 |
Testing of drug delivery systems for use in the treatment of narcotic addiction.
Topics: Animals; Delayed-Action Preparations; Dogs; Drug Implants; Haplorhini; Humans; Kinetics; Naltrexone; Narcotic Antagonists; Species Specificity; Substance-Related Disorders | 1976 |
Testing of drug delivery systems for use in the treatment of narcotic addiction.
Topics: Animals; Blood Proteins; Dogs; Drug Implants; Guinea Pigs; Haplorhini; Humans; Kinetics; Mice; Morphine; Naloxone; Naltrexone; Protein Binding; Rats; Reaction Time; Species Specificity; Substance-Related Disorders | 1975 |
Naloxone-precipitated withdrawal: a method for rapid induction onto naltrexone.
Topics: Adult; Drug Administration Schedule; Drug Therapy, Combination; Heroin Dependence; Humans; Male; Methadone; Methods; Naloxone; Naltrexone; Substance Withdrawal Syndrome; Substance-Related Disorders | 1977 |
Naltrexone treatment of opiate-dependent persons.
Topics: Adult; Humans; Male; Methadone; Middle Aged; Naloxone; Naltrexone; Narcotics; Substance-Related Disorders | 1977 |
Pharmacotherapy of opiate addiction.
Topics: Adolescent; Adult; Cyclazocine; Female; Heroin Dependence; Humans; Male; Methadone; Methadyl Acetate; Naltrexone; Opium; Substance-Related Disorders; United States | 1976 |
Reinstatement of precipitated narcotic withdrawal hypothermia in the rat.
Topics: Animals; Body Temperature; Female; Humans; Morphine; Naloxone; Naltrexone; Rats; Substance Withdrawal Syndrome; Substance-Related Disorders | 1976 |
Short-term effects of naltrexone in 155 heroin ex-addicts.
Topics: Abdomen; Administration, Oral; Blood Pressure; Brain; Dose-Response Relationship, Drug; Drug Evaluation; Heart; Heroin Dependence; Humans; Naloxone; Naltrexone; Pain; Respiration; Substance-Related Disorders; Time Factors | 1976 |
The theoretical basis of narcotic addiction treatment with narcotic antagonists.
Topics: Animals; Conditioning, Psychological; Drug Administration Schedule; Extinction, Psychological; Humans; Naltrexone; Narcotic Antagonists; Rats; Satiation; Self Medication; Substance Withdrawal Syndrome; Substance-Related Disorders | 1976 |
An analysis of naltrexone use--its efficacy, safety and potential.
Topics: Adult; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Methadone; Middle Aged; MMPI; Naloxone; Naltrexone; Outpatient Clinics, Hospital; Patient Compliance; Patient Dropouts; Personality Inventory; Substance-Related Disorders | 1976 |
Interactions of narcotics, narcotic antagonists, and ethanol during acute, chronic, and withdrawal states.
Topics: Alcohol Drinking; Animals; Animals, Newborn; Dextrorphan; Drug Interactions; Ethanol; Humans; Levorphanol; Male; Methadone; Methadyl Acetate; Mice; Mice, Inbred C57BL; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Rats; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors | 1976 |
Narcotic antagonists: naltrexone progress report: foreword.
Topics: Cyclazocine; Government Agencies; Heroin Dependence; Humans; Naltrexone; Narcotic Antagonists; Substance-Related Disorders; United States | 1976 |
A unit for delivering multiple drug treatment and prevention services.
Topics: Adolescent; Adult; Community Mental Health Services; Connecticut; Cyclazocine; Heroin Dependence; Humans; Methadone; Naltrexone; Psychotherapy, Group; Substance-Related Disorders; Vocational Education | 1975 |
On the role of chemotherapy in the treatment of heroin addiction.
Topics: Heroin Dependence; Humans; Methadone; Methadyl Acetate; Motivation; Naloxone; Naltrexone; Substance-Related Disorders | 1975 |
Patient deaths in a narcotic antagonist (naltrexone) and l-alpha-acetylmethadol program.
Topics: Adult; Heroin Dependence; Homicide; Humans; Male; Methadone; Methadyl Acetate; Naloxone; Naltrexone; Psychotropic Drugs; Substance-Related Disorders; Suicide | 1975 |
Lactic/glycolic acid polymers as narcotic antagonist delivery systems.
Topics: Animals; Behavior, Animal; Drug Implants; Glycolates; Humans; In Vitro Techniques; Lactates; Male; Mice; Naloxone; Naltrexone; Polymers; Structure-Activity Relationship; Substance-Related Disorders | 1975 |
Development of polylactic/glycolic acid delivery systems for use in treatment of narcotic addiction.
Topics: Animals; Biodegradation, Environmental; Drug Implants; Humans; Lactates; Male; Mice; Naloxone; Naltrexone; Polyglycolic Acid; Polymers; Substance-Related Disorders; Time Factors | 1975 |
Development of injectable microcapsules for use in the treatment of narcotic addiction.
Topics: Animals; Capsules; Delayed-Action Preparations; Humans; Injections; Lactates; Mice; Microspheres; Naloxone; Naltrexone; Polyglycolic Acid; Polymers; Substance-Related Disorders | 1975 |
Naltrexone abuse potential.
Topics: Adult; Ambulatory Care; Humans; Male; Middle Aged; Naltrexone; Substance-Related Disorders | 1992 |
Effects of beta-funaltrexamine on butorphanol dependence.
Topics: Animals; Behavior, Animal; Body Temperature; Body Weight; Butorphanol; Dose-Response Relationship, Drug; Injections, Intraventricular; Male; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains; Reinforcement Schedule; Substance Withdrawal Syndrome; Substance-Related Disorders | 1992 |
Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice.
Topics: Animals; Drug Implants; Drug Tolerance; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Indoles; Isothiocyanates; Male; Mice; Morphinans; Morphine; Naltrexone; Narcotic Antagonists; Nociceptors; Receptors, Opioid; Receptors, Opioid, delta; Substance-Related Disorders; Thiocyanates | 1991 |
Effects of long-term treatment with naltrexone on hepatic enzyme activity.
Topics: Administration, Oral; Adult; Alkaline Phosphatase; Antipyrine; Cannabis; Female; gamma-Glutamyltransferase; Half-Life; Humans; Liver; Male; Naltrexone; Substance-Related Disorders | 1991 |
"Paradoxical" analgesia and aggravated morphine dependence induced by opioid antagonists.
Topics: Animals; Body Weight; Indoles; Male; Morphinans; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Pain Measurement; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome; Substance-Related Disorders | 1990 |
Staying off the merry go round: prescribing habits for recovering patients.
Topics: Analgesics; Comorbidity; Disulfiram; Drug Prescriptions; Humans; Hypnotics and Sedatives; Mental Disorders; Naltrexone; Substance-Related Disorders; Tranquilizing Agents | 1990 |
Phosphodiesterase inhibitors potentiate opiate-antagonist discrimination by morphine-dependent rats.
Topics: 1-Methyl-3-isobutylxanthine; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Animals; Body Weight; Discrimination, Psychological; Dose-Response Relationship, Drug; Drug Synergism; Male; Morphine; Naltrexone; Narcotic Antagonists; Papaverine; Phosphodiesterase Inhibitors; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome; Substance-Related Disorders | 1989 |
From theory to practice: the planned treatment of drug users. Interview by Stanley Einstein.
Topics: Aftercare; Combined Modality Therapy; Humans; Methadone; Motivation; Naltrexone; Opioid-Related Disorders; Referral and Consultation; Substance-Related Disorders; Therapeutic Community | 1989 |
NIDA's Medication Development Program--1989.
Topics: Acquired Immunodeficiency Syndrome; Brain; Cocaine; Drug and Narcotic Control; Female; Heroin Dependence; Humans; Infant, Newborn; Methadone; Methadyl Acetate; Naltrexone; Pregnancy; Psychotropic Drugs; Research Support as Topic; Risk Factors; Substance Abuse, Intravenous; Substance-Related Disorders | 1989 |
A multicentre study to introduce naltrexone for opiate dependence in Spain.
Topics: Adult; Combined Modality Therapy; Female; Humans; Male; MMPI; Naltrexone; Narcotics; Opioid-Related Disorders; Prospective Studies; Psychotherapy; Psychotherapy, Group; Spain; Substance-Related Disorders | 1989 |
Locus ceruleus discharge characteristics of morphine-dependent rats: effects of naltrexone.
Topics: Action Potentials; Animals; Locus Coeruleus; Male; Morphine; Naltrexone; Rats; Rats, Inbred Strains; Substance-Related Disorders | 1989 |
Naltrexone treatment of bulimia: clinical and theoretical findings linking eating disorders and substance abuse.
Topics: Adult; Brain; Bulimia; Feeding Behavior; Female; Humans; Naltrexone; Receptors, Opioid; Substance-Related Disorders | 1987 |
Role of pituitary and related neuropeptides in alcoholism and pharmacodependence.
Topics: Adrenocorticotropic Hormone; Alcoholism; Animals; Arginine Vasopressin; beta-Endorphin; Brain; Endorphins; Haplorhini; Heroin Dependence; Humans; Melanocyte-Stimulating Hormones; Naltrexone; Neurotransmitter Agents; Peptides; Pituitary Gland; Rats; Reinforcement, Psychology; Reward; Substance-Related Disorders | 1986 |
Role of opioid antagonists in treating intravenous cocaine abuse.
Topics: Adult; Buprenorphine; Cocaine; Female; Humans; Injections, Intravenous; Male; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance-Related Disorders | 1989 |
Chronic naltrexone effect on cortisol.
Topics: Humans; Hydrocortisone; Naltrexone; Narcotics; Substance-Related Disorders | 1986 |
CSF endorphins in chronic opioid-dependent humans.
Topics: Endorphins; Humans; Male; Methadone; Naltrexone; Narcotics; Substance-Related Disorders | 1986 |
Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates.
Topics: Animals; Colon; Constipation; Diarrhea; Dose-Response Relationship, Drug; Glucuronates; Male; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains; Skin Temperature; Substance-Related Disorders | 1988 |
Naltrexone: lack of effect on hepatic enzymes.
Topics: Adult; Aspartate Aminotransferases; Heroin Dependence; Humans; L-Lactate Dehydrogenase; Liver; Liver Function Tests; Male; Methadone; Naltrexone; Substance-Related Disorders; Time Factors | 1988 |
Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers.
Topics: Adult; Clinical Protocols; Clonidine; Drug Therapy, Combination; Female; Heroin; Humans; Male; Naltrexone; Substance-Related Disorders | 1988 |
Primary care of parenteral substance abusers.
Topics: Acquired Immunodeficiency Syndrome; Administration, Intranasal; Antibodies, Viral; Body Weight; Cocaine; Female; Heart Diseases; Hepatitis; Heroin Dependence; HIV Antibodies; Humans; Injections, Intradermal; Injections, Intravenous; Kidney Diseases; Male; Menstruation Disturbances; Methadone; Naltrexone; Nervous System Diseases; Primary Health Care; Respiratory Tract Diseases; Substance-Related Disorders | 1986 |
The pros and cons of naltrexone detoxification.
Topics: Humans; Naltrexone; Substance-Related Disorders | 1987 |
The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone.
Topics: Adult; Blood Pressure; Clonidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Rate; Humans; Male; Methadone; Naltrexone; Substance Withdrawal Syndrome; Substance-Related Disorders | 1986 |
REM sleep deprivation decreases the grooming and shaking behaviour induced by enkephalinase inhibitor or opiate withdrawal.
Topics: Animals; Anti-Bacterial Agents; Glycopeptides; Grooming; Injections, Intraventricular; Male; Naltrexone; Narcotics; Neprilysin; Protease Inhibitors; Rats; Rats, Inbred Strains; Sleep Deprivation; Sleep, REM; Substance Withdrawal Syndrome; Substance-Related Disorders | 1985 |
Effects of beta-funaltrexamine in normal and morphine-dependent rhesus monkeys: observational studies.
Topics: Animals; Azocines; Behavior, Animal; Dose-Response Relationship, Drug; Injections, Intraventricular; Injections, Subcutaneous; Macaca mulatta; Morphine; Muscle Relaxation; Naloxone; Naltrexone; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors | 1985 |